<DOC>
	<DOCNO>NCT00689104</DOCNO>
	<brief_summary>The study intend test efficacy , safety tolerability two dos Mirabegron placebo compare efficacy safety active comparator patient symptoms overactive bladder .</brief_summary>
	<brief_title>Study Test Efficacy Safety Beta-3 Agonist Mirabegron ( YM178 ) Patients With Symptoms Overactive Bladder</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<mesh_term>Tolterodine Tartrate</mesh_term>
	<mesh_term>Mirabegron</mesh_term>
	<criteria>Subject willing able complete micturition diary questionnaire correctly Subject symptom overactive bladder ( urinary frequency urgency without urge incontinence ) ≥ 3 month Subject experience frequency micturition average ≥ 8 time per 24hour period 3day micturition diary period Subject must experience least 3 episode urgency ( grade 3 4 ) without incontinence , 3day micturition diary period Subject breastfeeding , pregnant , intend become pregnant study , childbearing potential , sexually active practice highly reliable method birth control Subject significant stress incontinence mixed stress/urge incontinence stress predominant factor Subject indwelling catheter practice intermittent selfcatheterization Subject diabetic neuropathy Subject evidence symptomatic urinary tract infection , chronic inflammation interstitial cystitis , bladder stone , previous pelvic radiation therapy previous current malignant disease pelvic organ Subject receives nondrug treatment include electrostimulation therapy Subject severe hypertension Subject know suspected hypersensitivity tolterodine , anticholinergic , YM178 , betaadrenoreceptor ( ßAR ) agonists , lactose inactive ingredient Subject treat investigational drug device within 30 day ( 90 day UK ) Subject average total daily urine volume &gt; 3000 mL record 3day micturition diary period Subject serum creatinine &gt; 150 umol/L , aspartate aminotransferase ( AST ) and/or alanine aminotransferase ( ALT ) &gt; 2x upper limit normal range ( ULN ) , gamma glutamyl transferase ( γGT ) &gt; 3x ULN Subject clinically significant abnormal electrocardiogram ( ECG )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Overactive bladder ( OAB )</keyword>
	<keyword>Frequency</keyword>
	<keyword>Micturition</keyword>
	<keyword>Urgency</keyword>
	<keyword>Urinary incontinence</keyword>
	<keyword>Urinary urge incontinence</keyword>
	<keyword>YM178</keyword>
</DOC>